Filing Details
- Accession Number:
- 0001333277-19-000034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-08 20:21:09
- Reporting Period:
- 2019-02-07
- Accepted Time:
- 2019-02-08 20:21:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1042074 | Cymabay Therapeutics Inc. | CBAY | Pharmaceutical Preparations (2834) | 943103561 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1110780 | Carl Goldfischer | C/O Cymabay Therapeutics, Inc. 7575 Gateway Boulevard, Suite 110 Newark CA 94560 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-02-07 | 2,335 | $5.00 | 2,335 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2019-02-07 | 9,340 | $5.50 | 11,675 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-02-07 | 11,675 | $9.02 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2019-02-07 | 2,335 | $0.00 | 2,335 | $5.00 |
Common Stock | Stock Option (right to buy) | Disposition | 2019-02-07 | 9,340 | $0.00 | 9,340 | $5.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2023-12-22 | No | 4 | M | Direct | |
0 | 2027-06-27 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.09, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Fully vested.